Physician profile
John R Sutton
NPI 1801812631
$7,806.28
in general payments reported to CMS, 2019-2025
34 companies · $1,468 in 2025
The $1,468 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $737 · 2021: $881 · 2022: $1,414 · 2023: $1,727 · 2024: $1,012 · 2025: $1,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,207.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.00 | 2019-2024 | |
| Corcept Therapeutics | $774.45 | 2019-2024 | Korlym |
| Lilly USA, LLC | $770.07 | 2019-2025 | Jardiance, Lyumjev, Mounjaro |
| Abbott Laboratories | $630.84 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $627.47 | 2021-2025 | Evenity, Prolia, Tavneos |
| Novo Nordisk INC | $469.66 | 2021-2025 | Sogroya, Wegovy |
| Mannkind Corporation | $414.32 | 2020-2025 | Afrezza |
| Xeris Pharmaceuticals, INC. | $370.80 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $240.29 | 2023-2025 | Yorvipath |
| Dexcom, INC. | $236.43 | 2022-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $234.08 | 2022-2023 | Minimed 770g, Minimed 780g |
| Horizon Therapeutics Plc | $221.10 | 2022-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $217.10 | 2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $168.56 | 2020-2025 | |
| Amryt Pharma Holdings LTD | $161.01 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.30 | 2023-2024 | Synthroid |
| Alexion Pharmaceuticals, INC. | $152.75 | 2023 | Strensiq |
| Ascensia Diabetes Care US INC. | $137.49 | 2023 | |
| Gilead Sciences, INC. | $123.70 | 2019 | |
| Soleno Therapeutics, INC. | $119.16 | 2025 | Vykat Xr |
| Radius Health, INC. | $117.73 | 2020-2024 | Tymlos |
| Insulet Corporation | $116.64 | 2025 | Omnipod |
| Grt US Holding, INC. | $106.96 | 2022 | |
| Biomarin Pharmaceutical INC. | $88.23 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.03 | 2021 | |
| Ibsa Pharma INC. | $70.56 | 2020-2021 | |
| Almatica Pharma LLC | $53.89 | 2025 | Teriparatide |
| Kowa Pharmaceuticals America, INC. | $44.46 | 2020 | |
| Opko Pharmaceuticals, LLC | $30.00 | 2019 | |
| Zealand Pharma US, INC. | $24.67 | 2022 | |
| Neurocrine Biosciences, INC. | $22.79 | 2024 | |
| Vistapharm, INC. | $21.99 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.24 | 2023 | |
| Kyowa Kirin, INC. | $13.51 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sutton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.